Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA): Notes Patent Potential
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $29.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
